These data suggest that the true clinical activity of cabozantinib is likely through disruption of tumor microvessel structure and provide further support for the hypothesis that the primary response to cabozantinib in our SCNPC studies was mediated through tumor endothelial cell VEGFR2 inhibition. Here, KDR is linked to neoplasm.